| Filed On | Filing |
|---|---|
| 10 Jan 2025 | SCHEDULE 13G/A |
| 08 Aug 2024 |
8-K: Bankruptcy or Receivership; Completion of Acquisition or Disposition of Assets +2 more
The relief set forth on the following pages, numbered three (3) through seventy-one (71), is ORDERED. |
| 31 Jul 2024 |
8-K: Regulation FD Disclosure
UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OFFOR THE NEW JERSEY In Re. Invitae Corporation Debtor(s) § § § § Case No. 24-11362 Lead Case No. 24-11362 Jointly Administered Monthly Operating Report Chapter 11 Re... |
| 01 Jul 2024 |
8-K: Regulation FD Disclosure
Case 24-11362-MBK Doc 701 Filed 06/28/24 Entered 06/28/24 15:22:06 Desc Main |
| 04 Jun 2024 |
8-K: Regulation FD Disclosure
UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OFFOR THE NEW JERSEY In Re. Invitae Corporation Debtor(s) § § § § Case No. 24-11362 Lead Case No. 24-11362 Jointly Administered Monthly Operating Report Chapter 11 Re... |
| 02 May 2024 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Case 24-11362-MBK Doc 390 Filed 04/30/24 Entered 04/30/24 19:59:54 Desc Main |
| 04 Apr 2024 |
8-K: Regulation FD Disclosure
UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OFFOR THE NEW JERSEY In Re. Invitae Corporation Debtor(s) § § § § Case No. 24-11362 Lead Case No. 24-11362 Jointly Administered Monthly Operating Report Chapter 11 Re... |
| 06 Mar 2024 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
SAN FRANCISCO – March 6, 2024 – Invitae (OTC: NVTA), a leading medical genetics company, today announced estimated unaudited fourth quarter and full year 2023 revenue, gross profit, and cash burn. |
| 21 Feb 2024 | 25-NSE |
| 14 Feb 2024 |
8-K: Entry into a Material Definitive Agreement; Bankruptcy or Receivership +3 more
THIS TRANSACTION SUPPORT AGREEMENT IS NOT AN OFFER OR ACCEPTANCE WITH RESPECT TO ANY SECURITIES OR A SOLICITATION OF ACCEPTANCES OF A CHAPTER 11 PLAN WITHIN THE MEANING OF SECTION 1125 OF THE BANKRUPTCY CODE. ANY SUCH OFFER OR SOLICITATI... |
| 13 Feb 2024 | SCHEDULE 13G/A |
| 13 Feb 2024 | SC 13G/A |
| 06 Feb 2024 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 05 Feb 2024 | AMENDMENT NO. 4 |
| 29 Jan 2024 | SC 13G/A |
| 29 Jan 2024 | SC 13G/A |
| 24 Jan 2024 |
8-K/A: Costs Associated with Exit or Disposal Activities
As previously announced and in connection with the consummation of the transaction described under Item 1.01 of the Original Report, the Company had initiated a workforce reduction. At the time of the Original Report, the Company was not... |
| 22 Jan 2024 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +2 more
SAN FRANCISCO – Jan. 22, 2024 – Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has completed the sale of certain reproductive health assets, which include carrier screening and non-invasive prenatal screenin... |
| 18 Jan 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
On behalf of Invitae Corporation (the “Company”), I am pleased to offer you an opportunity to receive a retention bonus of $________ (the “Retention Bonus”) if you agree to the terms and conditions of this letter agreement (this “Agreeme... |
| 12 Jan 2024 |
8-K/A: Costs Associated with Exit or Disposal Activities
As previously announced, on December 13, 2023, the Company committed to a workforce reduction and other cost saving initiatives as part of the Company’s efforts to reduce operating expenses. At the time of the Original Report, the Compan... |
Loading...